drugset / Trial / NCT05279300
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
Timeline
- Start
- 2022-03-28
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS5001 | Unknown | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | — |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |
| Background | Vincristine | Small molecule | — | Intravenous |